Video Experimental Relacionado
Updated: Aug 2, 2026
06:25
Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
La catalepsia inducida por haloperidol está mediada por los receptores postsinápticos de dopamina
Nature
|April 3, 1980
Resumen
Las drogas neuroelépticas causan catalepsia al bloquear los receptores de dopamina. Este estudio muestra que la catalepsia inducida por haloperidol en animales está mediada por receptores de dopamina ubicados postsinápticamente en las neuronas estriadas.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Farmacología Farmacología.
Sus antecedentes:
- Los fármacos neuroelépticos, como el haloperidol, bloquean los receptores de dopamina e inducen la catalepsia en los animales.
- Estudios anteriores implicaron a los receptores de dopamina estriatal en la catalepsia, pero no pudieron diferenciar las funciones pre y postsinápticas debido a los métodos de lesión.
Objetivo del estudio:
- Investigar las funciones específicas de los receptores estriados de dopamina postsinápticos y presinápticos en la catalepsia inducida por neurolepticos.
Principales métodos:
- Utilizó ácido caínico para destruir selectivamente los receptores postsinápticos de dopamina.
- Se empleó ablación cortical para destruir selectivamente los receptores presinápticos de dopamina.
Principales resultados:
- La catalepsia inducida por haloperidol se redujo significativamente después de la destrucción postsináptica del receptor de dopamina.
- La destrucción presináptica del receptor de dopamina no abolió la catalepsia.
Conclusiones:
- Los efectos catalépticos del haloperidol están mediados principalmente por los receptores de dopamina ubicados postsinápticamente en las neuronas estriadas.
Videos de Conceptos Relacionados
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...